Gilead Sciences halts Phase II trial of GS 9450 for chronic hepatitis C

Download PDF Copy

Apr 20 2010

NewsGuard 100/100 Score

Gilead Sciences, Inc. (Nasdaq:GILD) today announced the company is stopping its ongoing Phase II clinical trial of GS 9450, an investigational caspase inhibitor, in patients with chronic hepatitis C. This decision follows reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.

Patient safety is Gilead's top priority, and the company has therefore made the decision to halt this study immediately. Gilead will be conducting a thorough review of all available data to assess future clinical development of the compound.

Source Gilead Sciences

Posted in: Drug Trial News | Disease/Infection News

Tags: Chronic, Clinical Trial, Compound, Hepatitis, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Laboratory

Comments (0)

Download PDF Copy

Suggested Reading

Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches

Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches

Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients

Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients

AI reveals genetic links in aging, chronic diseases, and lifestyle factors across nine organ systems

AI reveals genetic links in aging, chronic diseases, and lifestyle factors across nine organ systems

Reducing processed meat consumption could reduce burden of chronic diseases in the USA, study suggests

Reducing processed meat consumption could reduce burden of chronic diseases in the USA, study suggests

COVID-19 increases chronic fatigue risk

COVID-19 increases chronic fatigue risk

Ozempic effective for patients with chronic kidney damage

Ozempic effective for patients with chronic kidney damage

Irregular sleep and poor REM sleep linked to higher risk of chronic diseases

Irregular sleep and poor REM sleep linked to higher risk of chronic diseases

How gut microbiome and fiber diversity shape chronic disease outcomes

How gut microbiome and fiber diversity shape chronic disease outcomes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Liver receptor mutations linked to liver dysfunction, cholesterol accumulation, and hepatitis